Literature DB >> 20439166

Endothelial cells as targets for chylomicron remnants.

Jonathan Dalla-Riva1, Elena Garonna, Jonathan Elliott, Kathleen M Botham, Caroline P Wheeler-Jones.   

Abstract

Endothelial dysfunction is characterised by pro-inflammatory/pro-coagulant changes in the endothelium and supports leukocyte adhesion and transmigration, key steps in early atherogenesis. There is emerging evidence that triacylglycerol-rich lipoproteins (TGRLs) present in the circulation during the postprandial phase influence vascular inflammation but the specific contribution of the remnant lipoprotein component of TGRLs is largely unexplored and the mechanistic basis of their actions poorly defined. This article provides a brief overview of the evidence supporting direct actions of these particles on endothelial cells and highlights the importance of their fatty acid composition and oxidative state as determinants of their cellular actions.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20439166     DOI: 10.1016/j.atherosclerosissup.2010.04.001

Source DB:  PubMed          Journal:  Atheroscler Suppl        ISSN: 1567-5688            Impact factor:   3.235


  3 in total

1.  Physical activity opposes coronary vascular dysfunction induced during high fat feeding in mice.

Authors:  Yoonjung Park; Frank W Booth; Sewon Lee; Mathew J Laye; Cuihua Zhang
Journal:  J Physiol       Date:  2012-06-06       Impact factor: 5.182

2.  Understanding postprandial inflammation and its relationship to lifestyle behaviour and metabolic diseases.

Authors:  Boudewijn Klop; Spencer D Proctor; John C Mamo; Kathleen M Botham; Manuel Castro Cabezas
Journal:  Int J Vasc Med       Date:  2011-09-25

3.  Endothelial HO-1 induction by model TG-rich lipoproteins is regulated through a NOX4-Nrf2 pathway.

Authors:  Sally H Latham Birt; Robert Purcell; Kathleen M Botham; Caroline P D Wheeler-Jones
Journal:  J Lipid Res       Date:  2016-05-16       Impact factor: 5.922

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.